



NEWS RELEASE

XDx Announces Appointment of Kenneth E. Ludlum as Chief Financial Officer

Brisbane, CA, March 24, 2014, XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive tests to monitor the immune status in transplant recipients, today announced the appointment of Kenneth E. Ludlum as Chief Financial Officer, effective immediately.

Mr. Ludlum has more than 25 years of experience in the medical device industry, most recently serving as the Vice President and Chief Financial Officer of EndoGastric Solutions, Inc., a medical device company based in San Mateo, California. His service as chief financial officer at several public companies has provided him with extensive financial and accounting experience, and knowledge of accounting principles, financial reporting rules, and regulations. He currently serves on the boards of several private and public companies. Mr. Ludlum holds a Bachelor of Science degree in business from Lehigh University and a Masters of Business Administration degree from Columbia University.

"We are very pleased to welcome Ken to the XDx executive team. He is joining at a pivotal point in our evolution and is extremely well-qualified to lead the company's finance and administration activities as we grow our transplant surveillance platform," said Peter Maag, President and Chief Executive Officer of XDx. "As a seasoned Chief Financial Officer and executive in the healthcare field, Ken has demonstrated strength in strategy and execution and he will be an instrumental member of the organization."

About AlloMap®

AlloMap MolecularTesting is a non-invasive gene expression test used to aid in the identification of heart transplant recipients who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.

About XDx

XDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive tests to monitor immune status in transplant recipients and autoimmune disease and potentially improve long-term patient outcomes. The company has commercialized AlloMap, which aids clinicians in identifying heart transplant recipients with stable graft function. Some of the AlloMap technology developed by XDx may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system.

For more information, please visit: www.XDx.com.

Contacts Company

Matthew Meyer
Chief Business Officer
XDx, Inc.
Tel: 415-287-2393
mmeyer@xdx.com